- Tumors1000+
- Cancer1000+
- Pathologic Processes1000+
- Pathology1000+
- Nervous System Diseases1000+
Any
<10 miles
<30 miles
<50 miles
<70 miles
Filter Results
Condition
- Tumors1000+
- Cancer1000+
- Pathologic Processes1000+
- Pathology1000+
- Nervous System Diseases1000+
Where are you looking?
How far are you willing to travel?Any
How old are you?
Trial Status
Recruiting statusPlacebo
Recruiting
Waitlist Available
Administration Type
Trial Phase
Biomarkers
Stage of Disease
- HER2 negative
- ER positive
- PD-L1 positive
- HER2 positive
- PR positive
- ER negative
- PR negative
- PD-L1 negative
- EGFR positive
- BRAF positive
- EGFR negative
- KRAS positive
- p16 positive
- ALK negative
- CD20 positive
- HLA-A positive
- BRCA1 positive
- BRCA2 positive
- MET positive
- IDH positive
- ALK positive
- CD19 positive
- HLA positive
- BRAF negative
- MYC positive
- HLA negative
- IDH negative
- HPV positive
- p16 negative
- MET negative
- ROS1 negative
- TP53 positive
- HR positive
- MSI-H positive
- PIK3CA positive
- RET positive
- ROS1 positive
- FLT3 positive
- HLA-A negative
- RB1 positive
- NRAS positive
- dMMR positive
- NF1 positive
- PALB2 positive
- BCL2 positive
- BRCA positive
- HPV negative
- RB1 negative
- RAS positive
- BCL6 positive
- ANA positive
- CCND1 positive
- KRAS negative
- NTRK positive
- BCR-ABL1 positive
- TP53 negative
- CD5 positive
- MSS positive
- PTEN positive
- RET negative
- anti-dsDNA positive
- FGFR2 positive
- HbSS positive
- MGMT negative
- PD-1 positive
- ARID1A positive
- ATM positive
- BRCA1 negative
- KIT positive
- MMR positive
- MSH2 positive
- RAS negative
- ctDNA positive
- BRCA2 negative
- CD30 positive
- FGFR positive
- MGMT positive
- MLH1 positive
- MMR negative
- MSH6 positive
- PMS2 positive
- BRIP1 positive
- CD123 positive
- CDK12 positive
- NRAS negative
- NTRK negative
- PD-1 negative
- RAD51 positive
- dMMR negative
- CD4 positive
- CHEK2 positive
- CLDN18.2 positive
- FANCA positive
- HBV DNA negative
- L858R positive
- MSI negative
- MSI-H negative
- NTRK1 positive
- Philadelphia Chromosome positive
- SMN1 positive
- p53 positive
- t(11;14) positive
- BARD1 positive
- CD19 negative
- CD22 positive
- Ex19del positive
- HBsAg positive
- HPV16 positive
- MSI positive
- NF2 positive
- del(17p) positive
- pMMR positive
- ASXL1 positive
- BAP1 positive
- BRCA negative
- CD20 negative
- CD3 positive
- CFTR positive
- COL7A1 positive
- Complex karyotype positive
- FLT3 negative
- HBV DNA positive
- HBsAg negative
- HR negative
- HRAS positive
- JAK2 positive
- KMT2A positive
- Ki-67 positive
- MSS negative
- RAD51C positive
- RAD51D positive
- RAF positive
- RF positive
- RUNX1 positive
- ABCA4 positive
- APC positive
- Anti-Smith positive
- CD8 positive
- DLL3 positive
- EBV positive
- EZH2 positive
- FGFR3 positive
- FMR1 positive
- GRN positive
- HBcAb negative
- HBcAb positive
- Ki67 positive
- MDM2 positive
- PTEN negative
- SF3B1 positive
- SMARCB1 positive
- SMN2 positive
- SRSF2 positive
- TMB positive
- TROP2 positive
- TTR positive
- U2AF1 positive
- ZRSR2 positive
- anti-Sm positive
- t(11;14)(q13;q32) positive
- AKT1 positive
- BCOR positive
- BCR-ABL positive
- CD33 positive
- CHEK1 positive
- DMD positive
- EPCAM positive
- FANCL positive
- FGFR1 positive
- GPC3 positive
- HRD positive
- MECP2 positive
- NPM1 positive
- PDGFRA positive
- PIK3CA negative
- Ph positive
- Philadelphia chromosome negative
- SMARCA4 positive
- SMARCB1 negative
- STK11 positive
- T790M positive
- TERT positive
- TROP2 negative
- ZnT8 positive
- t(14;16) positive
- t(4;14) positive
- t(8;21) negative
- \-5/del(5q) positive
- \-7 positive
- 1p negative
- APOL1 positive
- APP positive
- AR positive
- ATR positive
- ATRX positive
- BCL-2 positive
- BCL-6 positive
- BCR-ABL1 negative
- C5 positive
- C9orf72 positive
- Gleason Score 10
- Gleason Score 6
- Gleason Score 7
- Gleason Score 8
- Gleason Score 9
- Grade 1
- Grade 2
- Grade 3
- Grade 4
- Stage IV
- Stage III
- Stage II
- Stage I
- 1 Prior Chemotherapy Regimen for Metastatic Disease
- 1927nm Fractional Thulium Laser Treatment
- 30-day washout period after Erythropoietin-Stimulating Agent or IV Iron
- ALK TKI Therapy
- ARD-101
- Abrocitinib
- Activating EGFR mutation [exon 19 deletion or exon 21 (L858R) substitution mutation]
- Active Treatment for Cutaneous Squamous Cell Carcinoma
- Active Treatment for Non-Invasive Basal Cell Carcinoma
- Adalimumab
Trial Status
Recruiting statusPlacebo
Recruiting
Waitlist Available
Administration Type
Trial Phase
Biomarkers
Stage of Disease
11240 trials
Columbus, OH (<10 mi)
Waitlist
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial tests whether inclisiran injections can prevent serious heart problems in high-risk adults who haven't had a major heart event yet by lowering their cholesterol levels. Inclisiran is a long-acting treatment that significantly lowers cholesterol.
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 2 & 3
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing an injectable medication called efgartigimod PH20 SC in people with certain muscle inflammation diseases. The goal is to see if it helps improve their condition by lowering harmful proteins in their blood. The study focuses on patients with specific subtypes of these diseases who often don't respond well to usual treatments. Efgartigimod was developed for autoimmune diseases and has been approved for treating a specific muscle condition in adults.
Columbus, OH (<10 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial tests if adding a radioactive drug to standard hormone treatments can better treat men with advanced prostate cancer. The drug targets and kills cancer cells with radiation, while standard treatments block hormones that help cancer grow.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Columbus, OH (<10 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is comparing two different treatments for men with metastatic castration resistant prostate cancer who have previously been treated with an alternate androgen receptor downregulation therapy. The study will compare how well each treatment improves the participant's rPFS (progression free survival) or death.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Columbus, OH (<10 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial tests an inhaler with three medications to help people with severe asthma who don't respond well to usual treatments. The inhaler reduces inflammation, relaxes muscles around the airways, and keeps them open longer. The study aims to see if this combination is more effective and safe compared to other treatments.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Columbus, OH (<10 mi)
Waitlist
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial tests if injecting special cells from a patient's own fat can reduce pain and improve function in people with knee osteoarthritis. These cells have been investigated in various studies for their potential to treat knee osteoarthritis by reducing pain and improving function.
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Waitlist
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial will test a combination of drugs to see if they are effective in reducing the chance of cancer recurrence or developing new cancers.
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial compares a new treatment, frexalimab, with an existing pill, teriflunomide, in adults aged 18-55 who have relapsing multiple sclerosis. The study aims to see if frexalimab can reduce the frequency of symptom relapses better than teriflunomide. Participants will be monitored over several years.
Efficacy & Safety Awards
Pivotal Trial
Get notified when new Vitiligo trials are postedWe'll send you an email whenever new trials are posted
Columbus, OH (<10 mi)
Waitlist
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial will evaluate if the drug upadacitinib is safe and effective in treating vitiligo, a chronic autoimmune skin disease. 540 participants will be enrolled worldwide to receive either upadacitinib or a placebo in Period A, followed by upadacitinib in Period B.
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Waitlist
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing a new drug called TAK-279 to see if it can help people with moderate to severe plaque psoriasis. The study will compare TAK-279 to an existing treatment called apremilast, which is approved for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis. The goal is to find out if TAK-279 can better reduce the skin problems associated with this condition.
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing a new medication called NMRA-335140 to see if it helps people with major depressive disorder. It includes participants who have no safety concerns. The medication aims to improve mood by affecting brain chemicals.
Efficacy & Safety Awards
Pivotal Trial
No Placebo-Only Group
Columbus, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing a new medication called NMRA 335140 to see if it can help people with Major Depressive Disorder feel less depressed. The study involves an initial evaluation and a treatment phase where participants will receive either the medication or an inactive substance. The medication likely works by changing brain chemicals that affect mood.
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
Columbus, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing a medication called Pegozafermin to see if it can lower high levels of fats in the blood in people with severe hypertriglyceridemia. These patients have very high triglyceride levels, which can lead to serious health issues. The medication aims to reduce these fat levels to improve their health.
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial studied if digital therapies plus standard care can reduce symptoms of schizophrenia in teens & adults.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Columbus, OH (<10 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing a new diabetes medication called orforglipron to see if it is safer and more effective than insulin in people with type 2 diabetes who are overweight or obese and at higher risk for heart problems. The study will last several years and involve multiple visits.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing gotistobart, a new drug that helps the immune system fight advanced lung cancer in patients who haven't responded to other treatments. It works by blocking a protein that allows cancer cells to hide from the immune system.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Get notified when new Erosive Esophagitis trials are postedWe'll send you an email whenever new trials are posted
Columbus, OH (<10 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial tests BLI5100, an oral medication, in patients with Erosive Esophagitis (EE). It aims to see if BLI5100 can heal the esophagus and maintain its healing.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Columbus, OH (<10 mi)
Waitlist
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing a medication called ritlecitinib, which is taken as oral capsules. It aims to help adults and adolescents who have non-segmental vitiligo, a condition that causes skin to lose its color. The medication works by managing the immune system to stop the skin from losing its color.
Efficacy & Safety Awards
Pivotal Trial
1
2
3
…50